Skip to content Skip to footer

SERINA THERAPEUTICS, INC. (SER)

HomeSERINA THERAPEUTICS, INC. (SER)
Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.
AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )
September 29, 2026
Read more
Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.
Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )
September 28, 2026
Read more
Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.
Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )
September 25, 2026
Read more
Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.
Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24
September 23, 2026
Read more
Tribe Public CEO Presentation and Q&A webinar graphic featuring Serina Therapeutics CEO Steven Ledger, NYSE: SER, promoting “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” with a global network map, molecular imagery, and Register Now call to action.
Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )
September 21, 2026
Read more
Illustration of a bullish investment landscape showing AI-powered ecommerce, healthcare innovation, cybersecurity and market growth. Robots manage online-shopping fulfillment around an ecommerce screen, clinicians and researchers work in a modern medical setting, and professionals point toward rising stock charts and upward arrows, with the phrases “AI Commerce,” “Healthcare” and “Stay Engaged.”
A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )
September 14, 2026
Read more
Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )
September 9, 2026
Read more
Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.
Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )
September 8, 2026
Read more
April 27, 2026 – Nasdaq Strikes Record Highs & Oil Jumps While FOMC Hangs In The Wings -( $EPRX $INTG $NOK $NVDA $ORKA $TSLA Rise!)
April 27, 2026
Read more
April 24, 2026 – AI Chips, Hot PMIs, and Cooler Heads: A Week Where Macro Tried to Matter -( $AMZN $APLD $AVGO $EPRX $INTG $NOK $NVDA $OPEN $SOAR $WMT Rise!)
April 24, 2026
Read more